🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you for letting me participate in this nice review NickPowellLab Jonathan Digby-Bell and Giovanni!

Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes? ✍️ Abdullah Abdullah 📄 bit.ly/3h8KgHA #ViscMed #COVID19 #colitis #CytokineStorm

In the age of systemic therapies, there is still room for novel local treatments in ulcerative colitis. Phase 3 trial being planned - The Lancet Gastroenterology & Hepatology

Kindly invited for an Editorial on the very nice study by ⁦Rahul Kalla⁩, which predicted disease progression based on serum proteomic profiling in IBD. Accurate disease prognostic biomarkers and predictors of therapeutic response much needed in IBD! academic.oup.com/ecco-jcc/advan…

“Submitting your abstract to a virtual congress has many advantages. The audience which takes notice is considerably larger. The talk can additionally be accessed at any time on the virtual platform.” Raja Atreya, former UEG Rising Star & #UEGWeek Virtual 2020 Abstract Presenter

New content online: Location is important: differentiation between ileal and colonic Crohn’s disease dlvr.it/RvW0Ml

NEW! REVIEW Markus Neurath on #COVID19: biologic and immunosuppressive therapy in gastroenterology and hepatology go.nature.com/3jG6a8O

Anti-IL23 have shown high efficacy ... they are making a big impact for an increasingly precise therapy my_UEG Laura Ramos López GETECCU

How do you nutritionally manage acute severe flare of IBD? Please answer the Y-ECCO survey 👇 you might get a ticket to hearts and minds next year #ECCO2022 💃 D-ECCO survey.ecco-ibd.eu/index.php/1955…

We have an effective toolkit to help many people living with IBD. When deployed early in the disease course we can achieve deep and sustained remission for many patients. The following strategy [👇] is not perfect, but is cost-effective and can be adopted widely. NEW thread 🧵

Privileged to have conducted, together with #Michael Scharl, the 34th Annual German IBD Science Meeting (DACED) in Mainz. Excellent Research presented by groups from GER/AUT/CH. Fantastic Keynote Lecture by ⁦⁦James Lee⁩ . After 3 years, in presence again. Very nice!

Next up on the Podcast: Durable, Medication-Free Remission with anti-IL23 therapy in Crohn's Disease - Is this real, why does this happen, and what does it mean for our understanding of #IBD? Is intermittent #IBD therapy with close monitoring an option? medscape.com/viewarticle/96…

Linked Comment from Raja Atreya & Markus Neurath - Induction of microRNA-124 as a novel therapeutic concept in #ulcerativecolitis thelancet.com/journals/langa… #GITwitter #IBD

“Etrasimod could further expand the therapeutic armamentarium for ulcerative colitis and positioning of this therapy in treatment algorithms will require more data.” Raja Atreya and Markus F Neurath discuss the implications of the research: thelancet.com/journals/lance…